INmune Bio: Phase 2 XPro1595 neuroimaging slows neurodegeneration in high-inflammation AD; MSC therapy review published

Inmune Bio, Inc.

New PerpPD+ MRI imaging from Phase 2 MINDFuL trial shows trend toward slowed cortical disarray progression in early AD patients with high neuroinflammation (ADi).
Data presented at CTAD conference; reinforces prior directional improvements on cognitive, biomarker, and neuropsychiatric endpoints.
Additional MRI analyses from MINDFuL trial expected in 2026 to assess gray- and white-matter integrity.
INmune Bio publishes peer-reviewed article on MSC therapies, including CORDStrom platform; BLA/MAA filing for RDEB expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.